Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

• Status: RECRUITING
• Trial end date: 2029-07-30

Summary

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).

• Phase: PHASE3

Details

• Lead Sponsor: Amgen
• Treatments: abiraterone; cabazitaxel; enzalutamide